Anthralin in Topical Treatment of P... Jan 3, 2009
Combining anthralin with other treatments, including UVB treatments, PUVA (the use of the light-sensitizing drug psoralen plus ultraviolet light A), tazorac or topical steroids, may improve the response to treatment. What is the Ingram Regimen. (Suite101.com)
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years Jun 13, 2008
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of Psoralen Ultra-Violet A (PUVA) treatment, should be examined for the presence of non-melanoma skin cancer prior to and during treatment with HUMIRA. In clinical studies with another TNF antagonist, a higher rate of serious congestive heart failure (CHF) related adverse events including worsening CHF and new onset CHF have been reported ... HUMIRA is... (PR Newswire)
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity Jun 13, 2008
HUMIRA is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA. Abbott's Commitment to Immunology Abbott is focused on the discovery and development of innovative treatments for immunologic diseases. The Abbott Bioresearch Center, founded in 1989 in Worcester, Mass. (PR Newswire)
Psoralen and Ultraviolet A Light Therapy for Psoriasis Aug 16, 2007
PUVA in the Age of Biologics. Journal Watch Dermatology 2007: 1-1. (New England Journal of Medicine)
Tanning may protect against melanoma Mar 11, 2007
Effect of PUVA on plasma and skin immunoreactive alpha-melanocyte stimulating hormone concentrations. Br J Dermatol. (Food Consumer)
New analyses reinforce efficacy of Remicade in treatment of severe psoriasis Feb 3, 2007
Study of Psoriasis with Infliximab [REMICADE] Induction Therapy (SPIRIT) was a Phase 2, multi-center, double-blind, placebo-controlled study evaluating the use of REMICADE induction therapy in 249 people with severe plaque psoriasis who had previously received psoralen plus ultraviolet light A (PUVA) or systemic therapy for psoriasis. Trial participants were randomized to receive REMICADE 3 mg/kg, REMICADE 5 mg/kg or placebo at weeks 0, 2, and 6 and were assessed biweekly for 10 weeks. (EurekAlert!)
